With the above background, this study reported the real-world clinical efficacy and adverse reactions of HP combined with chemotherapy as neoadjuvant therapy in patients with HER2-positive breast cancer treated in two institutions from March 2019 to February 2022 in Hebei Province of North China. Here, ERBB2 is linked to breast cancer.